The Medical Advisor

Immune Systems Advisor Formerly The COVID Advisor — evidence-based analysis of long COVID, immune injury, and post-viral disease Review Article · Post-COVID & Post-Vaccine Syndrome A clinical review of the evidence base, dosing rationale, safety considerations, and monitoring strategy for the Base Spike Detox regimen in long COVID and post-vaccine injury syndromes — updated June 2026. Last Updated: June 2026 Authors: Editorial Team, Immune Systems Advisor Abstract Persistent SARS-CoV-2 spike protein — derived from infection, vaccination, or both — has been proposed as a pathophysiological driver of long COVID and post-vaccine inflammatory syndromes. Dr. Peter McCullough, a board-certified internist and cardiologist, has developed a three-agent over-the-counter regimen termed the "Base Spike Detox" that combines nattokinase (2,000 FU twice daily), ...

Abstract Background: Head and neck cancers (HNC), predominantly squamous cell carcinomas, remain a significant global health burden with substantial morbidity and mortality, particularly in advanced or recurrent disease. Despite progress in surgery, radiotherapy, and immunotherapy, treatment resistance and toxicity continue to limit long-term outcomes. Repurposed antiparasitic agents, including ivermectin and fenbendazole, have gained attention for their potential anticancer properties based on preclinical evidence and emerging anecdotal clinical observations. Objective: To evaluate the biological rationale, preclinical evidence, and real-world anecdotal data supporting the use of ivermectin and fenbendazole in head and neck cancers, and to contextualize these findings within current oncologic treatment paradigms. Methods: A narrative synthesis was conducted integrating mechanistic studies, preclinical oncology literature, and publicly available case reports involving ivermectin and fe...